Cambridge Antibody Technology Company Profile

20:35 EDT 17th March 2018 | BioPortfolio

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.


Milstein BuildingGranta Park
United Kingdom


Phone: 44 (0)1223 471 471
Fax: 44 (0)1223 471 472

News Articles [809 Associated News Articles listed on BioPortfolio]

Cambridge Enterprise: How Apollo Therapeutics is driving forward therapeutic innovation.

Iain Thomas, Head of Life Sciences at Cambridge University’s technology transfer arm, discusses the recent launch of Apollo Therapeutics, an ambitious collaboration between AstraZeneca, GlaxoSmithK...

Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The ...

RESPECT is a site-specific conjugation technology that targets select amino acid residues as a way of producing investigational homogeneous ADCs with defined drug-to-antibody ratios.  The Read mo...

‘Double Decker’ Antibody Technology Fights Cancer

NewsA new class of antibody-drug conjugates use a technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy.

#jobs #lifescience MedImmune: Intern – Antibody Discovery and Protein Engineering (FTC)

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MedImmune: Intern – Antibody Discovery and Protein Engineering (FTC) . ...

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M...

New Study: ‘Double Decker’ Antibody Technology Fights Cancer

JUPITER, Fla., Oct. 25, 2017 /PRNewswire-USNewswire/ — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), us...

Cullinan Oncology and MAB Discovery Collaborate on Novel Antibody Therapeutics

US Cullinan Oncology, based in Cambridge, MA, and German MAB Discovery (MABD) announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD's discovery platform.

'Double decker' antibody technology fights cancer

Scientists have created a new class of antibody-drug conjugates for cancer therapy, outlines a new report.

PubMed Articles [1897 Associated PubMed Articles listed on BioPortfolio]

Integration of Antibody Array Technology into Drug Discovery and Development.

Antibody arrays represent a high-throughput technique that enables the parallel detection of multiple proteins with minimal sample volume requirements. In recent years, antibody arrays have been widel...

Barcoded sequencing workflow for high throughput digitization of hybridoma antibody variable domain sequences.

Since the invention of Hybridoma technology by Milstein and Köhler in 1975, its application has greatly advanced the antibody discovery process. The technology enables both functional screening and l...

Toward rational antibody design: recent advancements in molecular dynamics simulations.

Because antibodies have become an important therapeutic tool, rational antibody design is a challenging issue involving various science and technology fields. From the computational aspect, many types...

How B-Cell Receptor Repertoire Sequencing Can Be Enriched with Structural Antibody Data.

Next-generation sequencing of immunoglobulin gene repertoires (Ig-seq) allows the investigation of large-scale antibody dynamics at a sequence level. However, structural information, a crucial descrip...

T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics.

Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30years, ...

Clinical Trials [2719 Associated Clinical Trials listed on BioPortfolio]

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™

The primary aim of this study is to demonstrate the maintenance of healthy peri-stomal skin over a two month period in subjects who use ConvaTec Moldable Technology™ Skin Barriers as par...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

Expanded Access Study of Iodine-131 Anti-B1 Antibody

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on...

JCV Antibody Program (STRATIFY-2)

Define the sero prevalence of JCV Antibody in the MS population and potentially stratify patients into lower or higher risk for developing PML based on antibody status.

Companies [1208 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Zenyth Therapeutics Limited

Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas ...

More Information about "Cambridge Antibody Technology" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Clinical Trials and PubMed Articles about Cambridge Antibody Technology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Companies in our database. You can also find out about relevant Cambridge Antibody Technology Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record